Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.72 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.70 |
| ▸ | AXL | P30530 | 1/20 | 0.68 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.68 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.68 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3822438 | 0.88 | RAB9A (0.59) | CYP19A1CYP17A1AXLPBRM1MKNK1 | |
| SCHEMBL3818666 | 0.86 | CYP19A1 (0.55) | CYP19A1CYP17A1AXLPBRM1MKNK1 | |
| SCHEMBL6649613 | 0.84 | CYP19A1 (0.59) | CYP19A1CYP17A1AXLPBRM1MKNK1 | |
| SCHEMBL3813261 | 0.82 | KDM4E (0.64) | CYP19A1CYP17A1RAB9AKDM4ENPC1 | |
| SCHEMBL6649362 | 0.82 | CYP19A1 (0.87) | CYP19A1AXLPBRM1MKNK1MKNK2 | |
| SCHEMBL6196239 | 0.81 | CYP19A1 (1.00) | CYP19A1AXLPBRM1MKNK1MKNK2 | |
| SCHEMBL6649329 | 0.81 | CYP17A1 (0.54) | CYP19A1CYP17A1RAB9AKDM4EALDH1A1 | |
| SCHEMBL19051355 | 0.81 | CYP19A1 (0.79) | CYP19A1CYP17A1AXLPBRM1MKNK1 | |
| SCHEMBL3821580 | 0.80 | KDM4E (0.61) | CYP19A1CYP17A1AXLPBRM1MKNK1 | |
| SCHEMBL6648628 | 0.80 | CYP19A1 (0.60) | CYP19A1CYP17A1AXLPBRM1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1348706-B1 | SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2009-08-19 | — | — | EP | disclosed |
| US-7067537-B2 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-27 | — | — | US | disclosed |
| US-20040072876-A1 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1348706-A1 | SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072876-A1 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | CYP17A1, CYP21A2, HSD17B1 | CYP19A1 10/4885CYP17A1 1/4885AXL 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.